Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Dormoi, Jérôme ^a,b   Briolant, Sébastien ^a,b,c,d   Pascual, Aurélie ^a,b   Desgrouas, Camille ^a   Travaillé, Christelle ^a   Pradines, Bruno ^a,b  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c Direction Interarmées du Service de Santé   (France)

^d INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

Author keywords

Antimalarial; Artemisinin; In vivo; Malaria; Plasmodium berghei; Resistance; Statin

Indexed keywords

ATORVASTATIN; CXCL3 CHEMOKINE; DIHYDROARTEMISININ; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 13; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; QUININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MALARIA; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; EXPERIMENTAL MODEL; FEMALE; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; MURINE MODEL; NONHUMAN; PARASITEMIA; PATHOGENESIS; PLASMODIUM BERGHEI; SURVIVAL; SURVIVAL RATE; THERAPY EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; INFLAMMATION; MALARIA, CEREBRAL; MICE; MICE, INBRED C57BL; PYRROLES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883178103     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-302     Document Type: Article

References (59)

1. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Dondorp A, Nosten F, Stepniewska K, Day N, White N, Lancet 2005 366 717 725 16125588 (Pubitemid 41207233)
2. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, et al. Lancet 2010 376 1647 1657 10.1016/S0140-6736(10)61924-1 21062666
3. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM, Lancet Infect Dis 2012 12 851 858 10.1016/S1473-3099(12)70181-0 22940027
4. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
5. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
6. Assessment of the management of cases of fever and malaria by general practitioners in the central Highlands of Madagascar, 2009-2010. Rakotoarivelo RA, Razakarison C, Gottot S, Ravony Harintsoa L, Randrianiriana G, Andriamanjato D, Harilalarisoa H, Ramaniraka I, Rakotondramanga J, Rafaliarivony N, Ranaivoson F, Rakotonirina JF, Desplats D, Med Sante Trop 2012 22 317 322 23174525
7. Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model-A unifying proposal for drug action. Haynes RK, Cheu KW, Chan HW, Wong HN, Li KY, Tang MM, Chen MJ, Guo ZF, Guo ZH, Sinniah K, Witte AB, Coghi P, Monti D, Chem Med Chem 2012 7 2204 2226 23112085
8. Antimalarial interaction of quinine and quinidine with clarithromycin. Pandey SK, Dwivedi H, Singh S, Siddiqui WA, Tripathi R, Parasitology 2012 140 406 413 23137860
9. Preventing antimalarial drug resistance through combinations. White NJ, Drug Resist Updat 1998 1 3 9 10.1016/S1368-7646(98)80208-2 17092790
10. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C, Antimicrob Agents Chemother 2007 51 2654 2655 10.1128/AAC.01330-06 17502414 (Pubitemid 47047361)
11. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusai T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 2248 2252 10.1128/AAC.01462-08 19307369
12. Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, Pradines B, J Antimicrob Chemother 2010 65 1387 1394 10.1093/jac/dkq173 20501488
13. Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B, Malar J 2010 9 139 10.1186/1475-2875-9-139 20497586
14. Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B, Antimicrob Agents Chemother 2010 54 966 967 10.1128/AAC.01006-09 19949060
15. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Borek-Dohalsky V, Huclova J, Barrett B, Nemec B, Ulc I, Jelinek I, Anal Bioanal Chem 2006 386 275 285 10.1007/s00216-006-0655-3 16924379 (Pubitemid 44327024)
16. Statins alone are ineffective in cerebral malaria but potentiate artesunate. Bienvenu AL, Picot S, Antimicrob Agents Chemother 2008 52 4203 4204 10.1128/AAC.00513-08 18779350
17. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, Pradines B, Malar J 2012 11 13 10.1186/1475-2875-11-13 22233563
18. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Lou J, Lucas R, Grau GE, Clin Microbiol Rev 2001 14 810 820 table of contents 10.1128/CMR.14.4.810-820.2001 11585786 (Pubitemid 32979632)
19. Gene expression analysis reveals early changes in several molecular pathways in cerebral malaria-susceptible mice versus cerebral malaria-resistant mice. Delahaye NF, Coltel N, Puthier D, Barbier M, Benech P, Joly F, Iraqi FA, Grau GE, Nguyen C, Rihet P, BMC Genomics 2007 8 452 10.1186/1471-2164-8-452 18062806 (Pubitemid 351280035)
20. Behavioural and histopathological alterations in mice with cerebral malaria. Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, Helbok R, Tannich E, Schmutzhard E, Neuropathol Appl Neurobiol 2006 32 177 188 10.1111/j.1365-2990. 2006.00706.x 16599946
21. Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria. Kobbe R, Schreiber N, May J, Jacobs T, Antimicrob Agents Chemother 2008 52 1583 1584 10.1128/AAC.01428-07 18268089 (Pubitemid 351522043)
22. Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Helmers AJ, Gowda DC, Kain KC, Liles WC, Am J Trop Med Hyg 2009 81 631 637 10.4269/ajtmh.2009.09-0204 19815878
23. Scanning electron microscopy of the neuropathology of murine cerebral malaria. Lackner P, Beer R, Helbok R, Broessner G, Engelhardt K, Brenneis C, Schmutzhard E, Pfaller K, Malar J 2006 5 116 10.1186/1475-2875-5-116 17125519 (Pubitemid 44903558)
24. Retinal pathology of pediatric cerebral malaria in Malawi. White VA, Lewallen S, Beare NA, Molyneux ME, Taylor TE, PLoS One 2009 4 4317 10.1371/journal.pone.0004317 19177166
25. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. Reis PA, Estato V, da Silva TI, D'Avila JC, Siqueira LD, Assis EF, Bozza PT, Bozza FA, Tibiriça EV, Zimmerman GA, Castro-Faria-Neto HC, PLoS Pathog 2012 8 1003099 10.1371/journal.ppat.1003099 23300448
26. Challenges in the determination of early predictors of cerebral malaria: lessons from the human disease and the experimental murine models. Martins YC, Carvalho LJ, Daniel-Ribeiro CT, Neuroimmunomodulation 2009 16 134 145 10.1159/000180268 19212133
27. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Hunt NH, Grau GE, Trends Immunol 2003 24 491 499 10.1016/S1471-4906(03) 00229-1 12967673 (Pubitemid 37088152)
28. Plasmodium berghei: cerebral malaria in CBA mice is not clearly related to plasma TNF levels or intensity of histopathological changes. Carvalho LJ, Lenzi HL, Pelajo-Machado M, Oliveira DN, Daniel-Ribeiro CT, Ferreira-da-Cruz MF, Exp Parasitol 2000 95 1 7 10.1006/expr.2000.4508 10864512 (Pubitemid 30415947)
29. Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Taoufiq Z, Pino P, N'Dilimabaka N, Arrouss I, Assi S, Soubrier F, Rebollo A, Mazier D, Malar J 2011 10 52 10.1186/1475-2875-10-52 21356073
30. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Greenwood J, Steinman L, Zamvil SS, Nat Rev Immunol 2006 6 358 370 10.1038/nri1839 16639429
31. Statins and the vascular endothelial inflammatory response. Greenwood J, Mason JC, Trends Immunol 2007 28 88 98 10.1016/j.it.2006.12.003 17197237 (Pubitemid 46178495)
32. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ, Eur J Clin Pharmacol 2006 62 1003 1009 10.1007/s00228-006-0203-2 17089111 (Pubitemid 44786491)
33. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, J Atheroscler Thromb 2010 17 1096 1107 10.5551/jat.5660 20675955
34. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO, Pediatrics 2005 116 682 688 10.1542/peds.2004-2090 16140708 (Pubitemid 44336686)
35. Effects of statin and lipoprotein metabolism in heart failure. Miura S, Saku K, J Cardiol 2010 55 287 290 10.1016/j.jjcc.2010.02.003 20350519
36. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ, BMJ 2008 337 2423 10.1136/bmj.a2423 19001495
37. MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Ohtsuka Y, Lee J, Stamm DS, Sanderson IR, Gut 2001 49 526 533 10.1136/gut.49.4.526 11559650 (Pubitemid 32896983)
38. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Yan XT, Tumpey TM, Kunkel SL, Oakes JE, Lausch RN, Invest Ophthalmol Vis Sci 1998 39 1854 1862 9727408
39. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T, Nature 2011 477 90 94 10.1038/nature10357 21886162
40. The C-C motif chemokine ligands CCL5, CCL11, and CCL24 induce the migration of circulating fibrocytes from patients with severe asthma. Isgro M, Bianchetti L, Marini MA, Bellini A, Schmidt M, Mattoli S, Mucosal Immunol 2013 6 718 724 10.1038/mi.2012.109 23149666
41. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD, Worthen GS, J Clin Invest 2012 122 974 986 10.1172/JCI60588 22326959
42. In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1beta-induced peritonitis. Song J, Wu C, Zhang X, Sorokin LM, J Immunol 2013 190 401 410 10.4049/jimmunol.1202286 23225890
43. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J, Hepatology 2012 56 2242 2254 10.1002/hep.25907 22711685
44. Cerebral malaria protection in mice by species-specific Plasmodium coinfection is associated with reduced CC chemokine levels in the brain. Clark CJ, Phillips RS, Parasite Immunol 2011 33 637 641 10.1111/j.1365-3024.2011. 01329.x 21851365
45. Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity. Steigerwald M, Moll H, Infect Immun 2005 73 2564 2567 10.1128/IAI.73.4.2564-2567.2005 15784607 (Pubitemid 40470864)
46. Plasmodium berghei ANKA infection in ICR mice as a model of cerebral malaria. Basir R, Rahiman SF, Hasballah K, Chong W, Talib H, Yam M, Jabbarzare M, Tie T, Othman F, Moklas M, Abdullah W, Ahmad Z, Iran J Parasitol 2012 7 62 74 23323093
47. IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. Villegas-Mendez A, Greig R, Shaw TN, de Souza JB, Gwyer Findlay E, Stumhofer JS, Hafalla JC, Blount DG, Hunter CA, Riley EM, Couper KN, J Immunol 2012 189 968 979 10.4049/jimmunol. 1200688 22723523
48. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J, Atherosclerosis 2006 189 408 413 10.1016/j.atherosclerosis.2005.12.022 16443229 (Pubitemid 44634488)
49. Statins and sepsis: multiple modifications at multiple levels. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG, Lancet Infect Dis 2007 7 358 368 10.1016/S1473-3099(07)70111-1 17448939 (Pubitemid 46590065)
50. CXCL4 and CXCL10 predict risk of fatal cerebral malaria. Wilson NO, Jain V, Roberts CE, Lucchi N, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N, Stiles JK, Dis Markers 2011 30 39 49 10.1155/2011/828256 21508508
51. Plasmodium berghei ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient C57BL/6 mice. Sarfo BY, Wilson NO, Bond VC, Stiles JK, Malar J 2011 10 69 10.1186/1475-2875-10-69 21439091
52. IL-12Rbeta2 is essential for the development of experimental cerebral malaria. Fauconnier M, Palomo J, Bourigault ML, Meme S, Szeremeta F, Beloeil JC, Danneels A, Charron S, Rihet P, Ryffel B, Quesniaux VF, J Immunol 2012 188 1905 1914 10.4049/jimmunol.1101978 22238458
53. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey JO, Nkrumah FK, Behr C, Hviid L, Lancet 1998 351 1768 1772 10.1016/S0140-6736(97)09439-7 9635949 (Pubitemid 28269187)
54. Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain. Hanum PS, Hayano M, Kojima S, Int Immunol 2003 15 633 640 10.1093/intimm/dxg065 12697663 (Pubitemid 36519400)
55. Algorithms to predict cerebral malaria in murine models using the SHIRPA protocol. Martins YC, Werneck GL, Carvalho LJ, Silva BP, Andrade BG, Souza TM, Souza DO, Daniel-Ribeiro CT, Malar J 2010 9 85 10.1186/1475-2875-9-85 20334682
56. Clinical review: severe malaria. Trampuz A, Jereb M, Muzlovic I, Prabhu RM, Crit Care 2003 7 315 323 10.1186/cc2183 12930555 (Pubitemid 36939551)
57. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. Carter JA, Mung'ala-Odera V, Neville BG, Murira G, Mturi N, Musumba C, Newton CR, J Neurol Neurosurg Psychiatry 2005 76 476 481 10.1136/jnnp.2004.043893 15774431 (Pubitemid 40486569)
58. Cognitive impairment after cerebral malaria in children: a prospective study. Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, John CC, Pediatrics 2007 119 360 e366 10.1542/peds.2006-2027 17224457 (Pubitemid 46397732)
59. Water and lipid soluble statins, [ https://www.gpnotebook.co.uk/ simplepage.cfm?ID=x20120104193906598025